

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: January 17, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/539,407
				Filing Date	January 17, 2006
				First Named Inventor	Laurent MEIJER
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	040388-0131
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	A1	WO	99/42088 A		LOEWENHEIM HUBERT et al.	8/26/1999	
	A2	WO	97/28842 A		CENTRE NAT RECH SCIENT et al.	6/12/1997	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A3	H. LOWENHEIM et al., "Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of corti", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 3/30/1999, vol. 96, no. 7, 3/30/1999, pp. 4084-4088.	
	A4	Ping CHEN et al., "p27Kip1 links cell proliferation to morphogenesis in the developing organ of Corti", DEVELOPMENT vol. 126, no. 8, April 1999, pp. 1581-1590.	
	A5	M. KNOCKAERT et al., "Pharmacological inhibitors of cyclin-dependent kinases", TRENDS IN PHARMACOLOGICAL SCIENCES, Elsevier, AMSTERDAM, NL, Vol. 23, No. 3, 9/1/2002, pp. 417-423.	
	A6	M. LEGRAVEREND et al., "Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 43, no. 7, 2000, pp. 1262-1272.	
	A7	M. LEGRAVEREND et al., "Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 7, April 7, 1998, pp. 793-798.	

Examiner Signature	/Laura Schuberg/	Date Considered	05/10/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.